What is a stock summary page? Click here for an overview.
Business Description
Mayne Pharma Group Ltd
NAICS : 325412
SIC : 2834
ISIN : AU000000MYX0
Description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.2 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -1.28 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.6 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.5 | |||||
| 3-Year EBITDA Growth Rate | 19.3 | |||||
| 3-Year EPS without NRI Growth Rate | -107.5 | |||||
| 3-Year Book Growth Rate | -13.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.85 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.08 | |||||
| 9-Day RSI | 29.4 | |||||
| 14-Day RSI | 43.67 | |||||
| 3-1 Month Momentum % | 64.87 | |||||
| 6-1 Month Momentum % | 81.1 | |||||
| 12-1 Month Momentum % | 2.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.4 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.42 | |||||
| Days Inventory | 163.19 | |||||
| Days Sales Outstanding | 166.59 | |||||
| Days Payable | 320.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.7 | |||||
| Shareholder Yield % | 0.46 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.91 | |||||
| Operating Margin % | -28.03 | |||||
| Net Margin % | -31.3 | |||||
| FCF Margin % | -2.73 | |||||
| ROE % | -26.77 | |||||
| ROA % | -11.31 | |||||
| ROIC % | -13.53 | |||||
| 3-Year ROIIC % | 24.85 | |||||
| ROC (Joel Greenblatt) % | -129.81 | |||||
| ROCE % | -11.52 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.4 | |||||
| PB Ratio | 1.31 | |||||
| Price-to-Operating-Cash-Flow | 721 | |||||
| EV-to-EBIT | -5.17 | |||||
| EV-to-Forward-EBIT | 711.83 | |||||
| EV-to-EBITDA | -15.99 | |||||
| EV-to-Forward-EBITDA | 6.91 | |||||
| EV-to-Revenue | 1.21 | |||||
| EV-to-Forward-Revenue | 1.1 | |||||
| EV-to-FCF | -41.59 | |||||
| Price-to-GF-Value | 1.17 | |||||
| Earnings Yield (Greenblatt) % | -19.34 | |||||
| FCF Yield % | -2.05 | |||||
| Forward Rate of Return (Yacktman) % | -19.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:MAYNF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mayne Pharma Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 267.674 | ||
| EPS (TTM) ($) | -1.024 | ||
| Beta | 2.24 | ||
| 3-Year Sharpe Ratio | 0.35 | ||
| 3-Year Sortino Ratio | 0.71 | ||
| Volatility % | 89.9 | ||
| 14-Day RSI | 43.67 | ||
| 14-Day ATR ($) | 0.068241 | ||
| 20-Day SMA ($) | 4.378 | ||
| 12-1 Month Momentum % | 2.91 | ||
| 52-Week Range ($) | 2.415 - 4.6 | ||
| Shares Outstanding (Mil) | 81.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mayne Pharma Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mayne Pharma Group Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mayne Pharma Group Ltd Frequently Asked Questions
What is Mayne Pharma Group Ltd(MAYNF)'s stock price today?
The current price of MAYNF is $4.18. The 52 week high of MAYNF is $4.60 and 52 week low is $2.42.
When is next earnings date of Mayne Pharma Group Ltd(MAYNF)?
The next earnings date of Mayne Pharma Group Ltd(MAYNF) is 2025-08-26 Est..
Does Mayne Pharma Group Ltd(MAYNF) pay dividends? If so, how much?
Mayne Pharma Group Ltd(MAYNF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers